Related Experiment Videos
Cyclophosphamide cardiac injury mimicking acute myocardial infarction
1Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
Insights
Cyclophosphamide (CY) can cause heart damage mimicking myocardial infarction, evidenced by ECG changes and elevated cardiac enzymes. Post-mortem analysis revealed diffuse myocardial injury, not vascular events, suggesting a direct toxic effect of CY.
Area of Science:
- Cardiology
- Oncology
- Toxicology
Background:
- Cyclophosphamide (CY) is a widely used chemotherapeutic agent.
- Cardiac complications associated with chemotherapy require careful monitoring.
- Distinguishing drug-induced cardiotoxicity from other cardiac events is crucial for patient management.
Observation:
- A patient presented with ST segment elevation and elevated cardiac isoenzymes, symptoms suggestive of myocardial infarction.
- The patient had received cyclophosphamide (CY) treatment.
- Clinical presentation strongly mimicked an acute myocardial infarction.
Findings:
- Post-mortem examination excluded local vascular events such as thrombus or vasospasm as the cause of cardiac damage.
- Histopathological findings indicated diffuse myocardial injury.
- The observed myocardial injury was determined to be secondary to cyclophosphamide (CY) administration.
Implications:
- This case highlights the potential for cyclophosphamide (CY) to induce significant myocardial injury.
- Clinicians should consider CY-induced cardiotoxicity in patients presenting with myocardial infarction-like symptoms during or after treatment.
- Further research into the mechanisms and early detection of CY cardiotoxicity is warranted to improve patient outcomes.
Abstract:
We report a patient in whom cyclophosphamide (CY) caused damage to the heart that was manifested by ST segment elevation and marked elevation of serum cardiac isoenzymes and mimicked myocardial infarction. Post-mortem examination did not reveal any local vascular event (e.g. thrombus or spasm) and suggested diffuse myocardial injury secondary to CY.